CYP17A1 and prostate carcinoma: Hence, based on a previous study showing that CYP17A1 inhibition reduces DHEA production, we aimed to study whether the inhibition of CYP17A1 is effective at suppressing glioblastomas using abiraterone, which is a well-known chemotherapeutic drug for prostate cancer.